Vaccines News and Research RSS Feed - Vaccines News and Research

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941. [More]
New research may help scientists develop treatments or vaccines for Dengue fever

New research may help scientists develop treatments or vaccines for Dengue fever

Two recent papers by a University of Colorado School of Medicine researcher and colleagues may help scientists develop treatments or vaccines for Dengue fever, West Nile virus, Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. [More]
Study: HIV-positive women respond well to vaccine against human papillomavirus

Study: HIV-positive women respond well to vaccine against human papillomavirus

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. [More]
UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

The global experts who study the deadliest infectious diseases recognized the contributions of Frederick A. Murphy and Thomas G. Ksiazek, professors at the University of Texas Medical Branch, with a Lifetime Achievement Award at the 6th annual International Symposium on Filoviruses. The filoviruses include Ebola and Marburg viruses that cause death in 50 to 90 percent of people infected. The current outbreak of Ebola virus raging in West Africa has caused more than 100 deaths so far. [More]
Pitt CVR and Sanofi Pasteur join forces to help assess effectiveness of dengue vaccine

Pitt CVR and Sanofi Pasteur join forces to help assess effectiveness of dengue vaccine

The University of Pittsburgh Center for Vaccine Research (CVR) and Sanofi Pasteur, the vaccines division of Sanofi, have entered a scientific collaboration to help assess the effectiveness of a dengue vaccine once introduced for immunization programs. [More]
Sanofi Korea launches gut health product, Probi Digestis

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters. [More]
Viewpoints: Sebelius withstood attacks, but wasn't 'warrior' for law; Burwell offers GOP chance to focus on law's problems

Viewpoints: Sebelius withstood attacks, but wasn't 'warrior' for law; Burwell offers GOP chance to focus on law's problems

Kathleen Sebelius was known for her patience and cool under savage attack by Republicans, who treated her as a stand-in for the health law. She sat through hearings calmly reciting talking points while they fumed and fulminated for their audience. But that turned out to be one of her biggest liabilities ... What the health law needed in its first years was a cheerful, populist warrior who could laugh at the truly ridiculous distortions and lies Republicans invented about it, and roar back with the truth. Instead, she came across as a mild technocrat. She never emerged from the defensive crouch she assumed after the law's calamitous debut (David Firestone, 4/11). [More]
Study: Immunization program in UK has reduced HPV infections in young women

Study: Immunization program in UK has reduced HPV infections in young women

Each year around 2,000-2,500 women are diagnosed with cervical cancer in England, the most common cancer in women under 35. Infection with high-risk human papillomavirus (HR HPV) types 16 and 18 is responsible for around 70-80% of cervical cancers. [More]
Highlights: Va. mental health care task force; pharmacist duties in N.C.; nurse practitioners in Conn.

Highlights: Va. mental health care task force; pharmacist duties in N.C.; nurse practitioners in Conn.

A selection of health policy stories from Virginia, North Carolina, New York, Connecticut, Minnesota, Florida, Iowa and Oregon. [More]
Scientists discover protein potentially good target for influenza A virus

Scientists discover protein potentially good target for influenza A virus

Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially good target for antiviral drugs directed against the influenza A virus. [More]

Too much of c-FLIPR protein can trigger autoimmune diseases

So-called c-FLIP proteins inhibit signaling cascades that can lead to apoptosis. This is important temporarily in the response to pathogens to ensure that lymphocytes, a type of immune cells, can proliferate sufficiently. [More]

Research team to investigate ways to develop novel immune therapies for HPV-associated cancers

Stand Up To Cancer and the Farrah Fawcett Foundation, along with the American Association for Cancer Research, SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]

Scientists identify enzyme that could be a useful target in treating asthma, cancer

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. [More]
Concise analysis of cancer drug delivery markets

Concise analysis of cancer drug delivery markets

Research and Markets (http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering. [More]

MD Anderson forms research alliance with GSK to identify new therapeutic approaches to combat cancer

The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]
Dream team aims to turn pancreatic cancer into treatable disease

Dream team aims to turn pancreatic cancer into treatable disease

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer. [More]